Ligand Pharmaceuticals Valuation
| LGND Stock | USD 111.89 0.81 0.73% |
At this time, the firm appears to be undervalued. Ligand Pharmaceuticals secures a last-minute Real Value of $120.26 per share. The latest price of the firm is $111.89. Our model forecasts the value of Ligand Pharmaceuticals from analyzing the firm fundamentals such as Profit Margin of 0.30 %, return on equity of 0.06, and Current Valuation of 1.9 B as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Ligand Pharmaceuticals' valuation include:
Price Book 2.5134 | Enterprise Value | Enterprise Value Ebitda 19.8634 | Price Sales 13.8707 | Forward PE 18.1488 |
Undervalued
Today
Please note that Ligand Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Ligand Pharmaceuticals is based on 3 months time horizon. Increasing Ligand Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Ligand stock is determined by what a typical buyer is willing to pay for full or partial control of Ligand Pharmaceuticals Incorporated. Since Ligand Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ligand Stock. However, Ligand Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 111.89 | Real 120.26 | Target 144.0 | Hype 112.12 | Naive 116.98 |
The real value of Ligand Stock, also known as its intrinsic value, is the underlying worth of Ligand Pharmaceuticals Company, which is reflected in its stock price. It is based on Ligand Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Ligand Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Ligand Pharmaceuticals Incorporated helps investors to forecast how Ligand stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ligand Pharmaceuticals more accurately as focusing exclusively on Ligand Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Ligand Pharmaceuticals' intrinsic value based on its ongoing forecasts of Ligand Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Ligand Pharmaceuticals' closest peers. If more than one evaluation category is relevant for Ligand Pharmaceuticals we suggest using both methods to arrive at a better estimate.
Ligand Pharmaceuticals Cash |
|
Ligand Valuation Trend
Comparing Ligand Pharmaceuticals' enterprise value against its market capitalization is a good way to estimate the value of Ligand Pharmaceuticals Incorporated uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Ligand Revenue by Product
Ligand Pharmaceuticals Total Value Analysis
Ligand Pharmaceuticals Incorporated is now estimated to have valuation of 1.9 B with market capitalization of 2.11 B, debt of 6.17 M, and cash on hands of 147.94 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Ligand Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.9 B | 2.11 B | 6.17 M | 147.94 M |
Ligand Pharmaceuticals Investor Information
About 98.0% of the company shares are owned by institutional investors. The book value of Ligand Pharmaceuticals was now reported as 44.84. The company has Price/Earnings To Growth (PEG) ratio of 1.53. Ligand Pharmaceuticals last dividend was issued on the 2nd of July 2010. The entity had 1603:1000 split on the 2nd of November 2022. Based on the key indicators related to Ligand Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Ligand Pharmaceuticals Incorporated is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in February.Ligand Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Ligand Pharmaceuticals has an asset utilization ratio of 16.68 percent. This indicates that the Company is making $0.17 for each dollar of assets. An increasing asset utilization means that Ligand Pharmaceuticals Incorporated is more efficient with each dollar of assets it utilizes for everyday operations.Ligand Pharmaceuticals Ownership Allocation
The majority of Ligand Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Ligand Pharmaceuticals Incorporated to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Ligand Pharmaceuticals. Please pay attention to any change in the institutional holdings of Ligand Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.Ligand Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 131.31 M. Net Income was 52.15 M with profit before overhead, payroll, taxes, and interest of 120.06 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Ligand Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Ligand Pharmaceuticals and how it compares across the competition.
About Ligand Pharmaceuticals Valuation
The stock valuation mechanism determines Ligand Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Ligand Pharmaceuticals. We calculate exposure to Ligand Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Ligand Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 110.7 M | 86.4 M | |
| Pretax Profit Margin | 0.44 | 0.46 | |
| Operating Profit Margin | 0.08 | 0.09 | |
| Net Profit Margin | 0.36 | 0.24 | |
| Gross Profit Margin | 0.66 | 0.67 |
Ligand Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Ligand Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 17.8 M | |
| Quarterly Earnings Growth Y O Y | 1.032 | |
| Forward Price Earnings | 18.1488 |
Ligand Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Ligand Pharmaceuticals Incorporated and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Ligand we look at many different elements of the entity such as Ligand's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Ligand Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Ligand Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Ligand Pharmaceuticals' worth.Complementary Tools for Ligand Stock analysis
When running Ligand Pharmaceuticals' price analysis, check to measure Ligand Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ligand Pharmaceuticals is operating at the current time. Most of Ligand Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ligand Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ligand Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ligand Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| CEOs Directory Screen CEOs from public companies around the world |